The SYNERGY-Outcomes Clinical Research Study for MASLDThe SYNERGY-Outcomes Clinical Research Study for MASLD Facebook ad: “MASLD Study”
Ran for 6 days, from September 9 to September 15, 2026, the last day Crush saw it.
Run by The SYNERGY-Outcomes Clinical Research Study for MASLD on Facebook. Crush is not the advertiser and does not verify its claims. See this ad in Meta's Ad Library(opens in a new tab)
Want an ad like this for your product?
Crush makes new ad images for your product from this ad: your logo, your product photo, your offer.
Trials from $19.95 USD, then $79.95 USD a month. Cancel anytime.
About this ad
- Meta Ad Library ID
- 28282741361347157
- Platforms
- Facebook and Instagram
- Relaunches
- 4
Ad text
Fatty liver disease, also known as metabolic dysfunction-associated steatotic liver disease (MASLD), is a silent condition that often progresses quickly. People living with MASLD may be eligible for a clinical research study investigating potential treatment options. Learn more.
Where the ad sends people
trials.lilly.com
MASLD Study
The main purpose of the SYNERGY-OUTCOMES study is to find out whether retatrutide and tirzepatide can prevent major adverse liver outcomes (MALO) in people with high-risk metabolic dysfunction-associated steatotic liver disease (MASLD). The study will enroll adults who have MASLD based on non-invasi...
Learn more: trials.lilly.com(opens in a new tab)
